Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Mar;91(3):804–811. doi: 10.1172/JCI116300

Pathological and immunological effects of ingesting L-tryptophan and 1,1'-ethylidenebis (L-tryptophan) in Lewis rats.

L A Love 1, J I Rader 1, L J Crofford 1, R B Raybourne 1, M A Principato 1, S W Page 1, M W Trucksess 1, M J Smith 1, E M Dugan 1, M L Turner 1, et al.
PMCID: PMC288031  PMID: 8450062

Abstract

The eosinophilia-myalgia syndrome (EMS) has been associated with ingestion of L-tryptophan (L-TRP) produced by a single manufacturer. Epidemiological data implicated 1,1'-ethylidenebis (L-tryptophan) (EBT) (peak 97 or peak E) as a possible etiologic agent. We showed previously that Lewis rats treated with the L-TRP implicated in EMS develop fasciitis and perimyositis similar to those seen in human EMS. We now report the pathology associated with the treatment of Lewis rats with synthetic EBT and/or L-TRP. All animals treated for 6 wk with case-associated L-TRP or EBT developed significant myofascial thickening, compared with animals in the vehicle control and control L-TRP groups. However, even those animals receiving the control L-TRP showed a mild but significant increase in the thickness of the myofascia, compared with vehicle-treated control animals. All animals except vehicle controls also exhibited significant pancreatic pathology, including fibrosis and acinar changes. Only animals treated with case-associated L-TRP for 6 wk showed evidence of immune activation with increased frequency of CD8, Ia, and IL-2 receptor-positive cells in the peripheral blood. Animals receiving L-TRP or EBT for < 6 wk did not show significant differences in myofascial thickness, although these animals did show pancreatic acinar changes. Although these results demonstrate for the first time the pathological effects of EBT, they do not rule out the possibility that other impurities in the EMS-case-associated L-TRP may also contribute to some of the features of EMS.

Full text

PDF
804

Images in this article

806Image
on p.806
806Image
on p.806
806Image
on p.806
806Image
on p.806
808Image
on p.808
808Image
on p.808
808Image
on p.808
808Image
on p.808

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belongia E. A., Hedberg C. W., Gleich G. J., White K. E., Mayeno A. N., Loegering D. A., Dunnette S. L., Pirie P. L., MacDonald K. L., Osterholm M. T. An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl J Med. 1990 Aug 9;323(6):357–365. doi: 10.1056/NEJM199008093230601. [DOI] [PubMed] [Google Scholar]
  2. Blauvelt A., Falanga V. Idiopathic and L-tryptophan-associated eosinophilic fasciitis before and after L-tryptophan contamination. Arch Dermatol. 1991 Aug;127(8):1159–1166. [PubMed] [Google Scholar]
  3. CHEN G., BOHNER B. A confirmatory test for mephenesin-like action of a compound on mice. Proc Soc Exp Biol Med. 1958 Feb;97(2):344–346. doi: 10.3181/00379727-97-23738. [DOI] [PubMed] [Google Scholar]
  4. Campagna A. C., Blanc P. D., Criswell L. A., Clarke D., Sack K. E., Gold W. M., Golden J. A. Pulmonary manifestations of the eosinophilia-myalgia syndrome associated with tryptophan ingestion. Chest. 1992 May;101(5):1274–1281. doi: 10.1378/chest.101.5.1274. [DOI] [PubMed] [Google Scholar]
  5. Chiba S., Miyagawa K., Tanaka T., Moriya K., Takahashi K., Hirai H., Takaku F. Tryptophan-associated eosinophilia-myalgia syndrome and pancreatitis. Lancet. 1990 Jul 14;336(8707):121–121. doi: 10.1016/0140-6736(90)91641-m. [DOI] [PubMed] [Google Scholar]
  6. Crofford L. J., Rader J. I., Dalakas M. C., Hill R. H., Jr, Page S. W., Needham L. L., Brady L. S., Heyes M. P., Wilder R. L., Gold P. W. L-tryptophan implicated in human eosinophilia-myalgia syndrome causes fasciitis and perimyositis in the Lewis rat. J Clin Invest. 1990 Nov;86(5):1757–1763. doi: 10.1172/JCI114902. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Emslie-Smith A. M., Engel A. G., Duffy J., Bowles C. A. Eosinophilia myalgia syndrome: I. Immunocytochemical evidence for a T-cell-mediated immune effector response. Ann Neurol. 1991 May;29(5):524–528. doi: 10.1002/ana.410290512. [DOI] [PubMed] [Google Scholar]
  8. Fries J. F., Lindgren J. A., Bull J. M. Scleroderma-like lesions and the carcinoid syndrome. Arch Intern Med. 1973 Apr;131(4):550–553. doi: 10.1001/archinte.1973.00320100078010. [DOI] [PubMed] [Google Scholar]
  9. Graham J. R. Cardiac and pulmonary fibrosis during methysergide therapy for headache. Am J Med Sci. 1967 Jul;254(1):1–12. doi: 10.1097/00000441-196707000-00001. [DOI] [PubMed] [Google Scholar]
  10. Grant G. Anti-nutritional effects of soyabean: a review. Prog Food Nutr Sci. 1989;13(3-4):317–348. [PubMed] [Google Scholar]
  11. Hankes L. V., De Bruin E., Jansen C. R., Vorster L., Schmaeler M. Metabolism of 14C-labelled L-tryptophan, L-kynurenine and hydroxy-L-kynurenine in miners with scleroderma. S Afr Med J. 1977 Mar 19;51(12):383–390. [PubMed] [Google Scholar]
  12. Hertzman P. A., Blevins W. L., Mayer J., Greenfield B., Ting M., Gleich G. J. Association of the eosinophilia-myalgia syndrome with the ingestion of tryptophan. N Engl J Med. 1990 Mar 29;322(13):869–873. doi: 10.1056/NEJM199003293221301. [DOI] [PubMed] [Google Scholar]
  13. James T. N., Kamb M. L., Sandberg G. A., Silver R. M., Kilbourne E. M. Postmortem studies of the heart in three fatal cases of the eosinophilia-myalgia syndrome. Ann Intern Med. 1991 Jul 15;115(2):102–110. doi: 10.7326/0003-4819-115-2-102. [DOI] [PubMed] [Google Scholar]
  14. Kamb M. L., Murphy J. J., Jones J. L., Caston J. C., Nederlof K., Horney L. F., Swygert L. A., Falk H., Kilbourne E. M. Eosinophilia-myalgia syndrome in L-tryptophan-exposed patients. JAMA. 1992 Jan 1;267(1):77–82. doi: 10.1001/jama.267.1.77. [DOI] [PubMed] [Google Scholar]
  15. Kaufman L. D., Seidman R. J. L-tryptophan-associated eosinophilia-myalgia syndrome: perspective of a new illness. Rheum Dis Clin North Am. 1991 May;17(2):427–441. [PubMed] [Google Scholar]
  16. Longnecker D. S. Environmental factors and diseases of the pancreas. Environ Health Perspect. 1977 Oct;20:105–112. doi: 10.1289/ehp.7720105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Mayeno A. N., Lin F., Foote C. S., Loegering D. A., Ames M. M., Hedberg C. W., Gleich G. J. Characterization of "peak E," a novel amino acid associated with eosinophilia-myalgia syndrome. Science. 1990 Dec 21;250(4988):1707–1708. doi: 10.1126/science.2270484. [DOI] [PubMed] [Google Scholar]
  18. Philen R. M., Eidson M., Kilbourne E. M., Sewell C. M., Voorhees R. Eosinophilia-myalgia syndrome. A clinical case series of 21 patients. New Mexico Eosinophilia-Myalgia Syndrome Study Group. Arch Intern Med. 1991 Mar;151(3):533–537. doi: 10.1001/archinte.151.3.533. [DOI] [PubMed] [Google Scholar]
  19. Seidman R. J., Kaufman L. D., Sokoloff L., Miller F., Iliya A., Peress N. S. The neuromuscular pathology of the Eosinophilia-Myalgia syndrome. J Neuropathol Exp Neurol. 1991 Jan;50(1):49–62. doi: 10.1097/00005072-199101000-00004. [DOI] [PubMed] [Google Scholar]
  20. Silver R. M., Heyes M. P., Maize J. C., Quearry B., Vionnet-Fuasset M., Sternberg E. M. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan. N Engl J Med. 1990 Mar 29;322(13):874–881. doi: 10.1056/NEJM199003293221302. [DOI] [PubMed] [Google Scholar]
  21. Singer M. V., Niebel W., Jansen J. B., Hoffmeister D., Gotthold S., Goebell H., Lamers C. B. Pancreatic secretory response to intravenous caerulein and intraduodenal tryptophan studies: before and after stepwise removal of the extrinsic nerves of the pancreas in dogs. Gastroenterology. 1989 Mar;96(3):925–934. [PubMed] [Google Scholar]
  22. Stachow A., Jablonska S., Skiendzielewska A. 5-Hydroxytryptamine and tryptamine pathways in scleroderma. Br J Dermatol. 1977 Aug;97(2):147–154. doi: 10.1111/j.1365-2133.1977.tb15060.x. [DOI] [PubMed] [Google Scholar]
  23. Stachów A. Kolagen i choroby zwiazane z zaburzeniami jego metabolizmu. Przegl Dermatol. 1978 Jul-Aug;65(4):361–370. [PubMed] [Google Scholar]
  24. Sternberg E. M., Van Woert M. H., Young S. N., Magnussen I., Baker H., Gauthier S., Osterland C. K. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med. 1980 Oct 2;303(14):782–787. doi: 10.1056/NEJM198010023031403. [DOI] [PubMed] [Google Scholar]
  25. Strongwater S. L., Woda B. A., Yood R. A., Rybak M. E., Sargent J., DeGirolami U., Smith T. W., Varnis C., Allen S., Murphy K. Eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Analysis of four patients and implications for differential diagnosis and pathogenesis. Arch Intern Med. 1990 Oct;150(10):2178–2186. [PubMed] [Google Scholar]
  26. Swygert L. A., Maes E. F., Sewell L. E., Miller L., Falk H., Kilbourne E. M. Eosinophilia-myalgia syndrome. Results of national surveillance. JAMA. 1990 Oct 3;264(13):1698–1703. [PubMed] [Google Scholar]
  27. Teff K. L., Young S. N. Effects of carbohydrate and protein administration on rat tryptophan and 5-hydroxytryptamine: differential effects on the brain, intestine, pineal, and pancreas. Can J Physiol Pharmacol. 1988 Jun;66(6):683–688. doi: 10.1139/y88-108. [DOI] [PubMed] [Google Scholar]
  28. Toyo'oka T., Yamazaki T., Tanimoto T., Sato K., Sato M., Toyoda M., Ishibashi M., Yoshihira K., Uchiyama M. Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography. Chem Pharm Bull (Tokyo) 1991 Mar;39(3):820–822. doi: 10.1248/cpb.39.820. [DOI] [PubMed] [Google Scholar]
  29. Varga J., Uitto J., Jimenez S. A. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med. 1992 Jan 15;116(2):140–147. doi: 10.7326/0003-4819-116-2-140. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES